Abstract
In this study, we investigated the effects of migration inhibitory factor (rhMIF) on angiogenesis-related signaling cascades and apoptosis in human endothelial cells (ECs). We show that in vitro rhMIF induces migration and tube formation in Matrigel of human dermal microvascular endothelial cells (HMVECs), with potency comparable to that of basic fibroblast growth factor. In vivo, rhMIF induces angiogenesis in Matrigel plugs and in the corneal bioassay. Using panels of relatively specific kinase inhibitors, antisense oligonucleotides, and dominant-negative mutants, we show that mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) are critical for MIF-dependent HMVEC migration, whereas Src and p38 kinases are nonessential. Moreover, we demonstrate that rhMIF induces time-dependent increases in phosphorylation levels of MEK1/2, Erk1/2, and Elk-1, as well as PI3K, and its effector kinase, Akt, in HMVECs. Studies with dominant-negative mutants and antisense oligonucleotides corroborate these effects in HMVECs. Furthermore, we demonstrate that rhMIF-induced angiogenesis in the rat cornea in vivo and in the ex vivo endothelial cell morphogenesis assay is also MAPK- and PI3K-dependent. Our findings support a role for MIF as an angiogenic factor and provide a rationale for the use of MIF as a therapeutic inducer of neovascularization in the development of collateral circulation in coronary artery disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Angiogenesis Inducing Agents / pharmacology*
-
Animals
-
Cell Line
-
Cell Movement / drug effects
-
Chromones / pharmacology
-
Cornea / blood supply
-
DNA-Binding Proteins*
-
Dose-Response Relationship, Drug
-
Endothelium, Vascular / cytology
-
Endothelium, Vascular / drug effects*
-
Endothelium, Vascular / metabolism
-
Enzyme Inhibitors / pharmacology
-
Flavonoids / pharmacology
-
Humans
-
Macrophage Migration-Inhibitory Factors / pharmacology*
-
Mice
-
Mice, Inbred C57BL
-
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
Mitogen-Activated Protein Kinases / genetics
-
Mitogen-Activated Protein Kinases / metabolism*
-
Morpholines / pharmacology
-
Mutation
-
Neovascularization, Physiologic / drug effects
-
Oligonucleotides, Antisense / pharmacology
-
Phosphatidylinositol 3-Kinases / metabolism*
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphorylation
-
Protein Serine-Threonine Kinases*
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-akt
-
Rats
-
Recombinant Proteins / pharmacology
-
Signal Transduction / drug effects
-
Transcription Factors*
-
ets-Domain Protein Elk-1
Substances
-
Angiogenesis Inducing Agents
-
Chromones
-
DNA-Binding Proteins
-
ELK1 protein, human
-
Elk1 protein, mouse
-
Elk1 protein, rat
-
Enzyme Inhibitors
-
Flavonoids
-
Macrophage Migration-Inhibitory Factors
-
Morpholines
-
Oligonucleotides, Antisense
-
Phosphoinositide-3 Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Recombinant Proteins
-
Transcription Factors
-
ets-Domain Protein Elk-1
-
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
-
AKT1 protein, human
-
Akt1 protein, rat
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one